

SUPPLEMENTARY INFORMATION

Essential turmeric oils enhance anti-inflammatory efficacy of curcumin in dextran sulfate sodium-induced colitis

Shusuke Toden, Arianne L. Theiss, Xuan Wang and Ajay Goel

Supplementary Table 1: Mathematical comparison of DAI associated parameters between doses for each curcumin treatment

Day 5				Day 7					
	Dose comparison	P-values	Dose comparison	P-values	Dose comparison	P-values	Dose comparison	P-values	
	Standard		ETO		Standard		ETO		
DAI	5 v 25	0.764	5 v 25	0.056	DAI	5 v 25	0.937	5 v 25	0.13
	25 v 50	0.248	25 v 50	0.033		25 v 50	0.463	25 v 50	0.027
	5 v 50	0.143	5 v 50	0.0001		5 v 50	0.499	5 v 50	0.0003
Weight change	5 v 25	0.556	5 v 25	0.022	Weight change	5 v 25	0.848	5 v 25	0.05
	25 v 50	0.023	25 v 50	0.256		25 v 50	0.075	25 v 50	0.071
	5 v 50	0.071	5 v 50	0.0007		5 v 50	0.099	5 v 50	0.0003
Stool consistency	5 v 25	0.872	5 v 25	0.477	Stool consistency	5 v 25	0.769	5 v 25	0.665
	25 v 50	0.267	25 v 50	0.058		25 v 50	0.487	25 v 50	0.187
	5 v 50	0.325	5 v 50	0.01		5 v 50	0.661	5 v 50	0.081
Fecal bleeding	5 v 25	0.57	5 v 25	0.099	Fecal bleeding	5 v 25	0.787	5 v 25	0.165
	25 v 50	0.804	25 v 50	0.113		25 v 50	0.751	25 v 50	0.061
	5 v 50	0.42	5 v 50	0.002		5 v 50	0.942	5 v 50	0.001

DAI: Disease activity index

Supplementary Table 2: Mathematical comparison between ETO- and standard curcumin in DAI associated parameters

P-Values				
Dose (mg/kg)	Day 3	Day 5	Day 7	Overall
DAI				
5	0.73	0.657	0.301	0.344
25	0.851	0.279	0.529	0.429
50	0.921	0.237	0.043	0.08
Weight changes				
5	0.739	0.505	0.405	0.562
25	0.321	0.002	0.003	0.0008
50	0.739	0.184	0.005	0.024
Stool consistency				
5	1	0.362	0.274	0.274
25	0.656	0.656	0.729	0.849
50	1	0.412	0.781	0.549
Fecal bleeding				
5	0.624	0.769	0.172	0.271
25	0.633	0.873	0.873	0.682
50	1	0.493	0.005	0.156




DAI: Disease activity index

Supplementary Table 3: Primer lists

Primers	Sequence
FOXP3 (foward)	5'-GGTACACCCAGGAAAGACAG
	5'-ATCCAGGAGATGATCTGCTTG
IL10 (forward)	5'-GGTGCCAAGCCTATCGGA
	5'-ACCTGCTCCACTGCCTTGCT
IL-11 (forward)	5'-CTGCAAGCCCCACTGGAA
	5'-AGGCCAGGCGAGACATCA
CCL17 (forward)	5'-CCCATGAAGACCTTCACCTC
	5'-CATCCCTGGAACACTCCACT
CXCL5 (forward)	5'-CTCAGTCATAGCCGCAACCGAGC
	5'-CGCTTCTTCCACTGCGAGTGC
18S (forward)	5'- CCCCTCGATGCTCTTAGCTGAGTGT
	5'- CGCCGGTCCAAGAATTTCACCTCT


Supplementary Figure 1: ETO-curcumin exerts superior anti-inflammatory effects compared to standard curcumin and ETO on DSS-induced inflammation at 50 mg/kg body weight **A)** Graphical representation of curcumin treatment strategy **B)** Changes in individual categories of DAI (top), body weight changes, stool consistency and stool bleeding (left-right). Changes in disease activity index (DAI) (bottom). *= p < 0.05, **= p < 0.01, ***= p < 0.001.

Supplementary Figure 2: Effects of ETO-curcumin and standard curcumin on DSS-induced inflammation at 5 mg/kg body weight daily gavaging **A)** Graphical representation of curcumin treatment strategy **B)** Changes in individual categories of DAI (top), body weight changes, stool consistency and stool bleeding (left-right). Changes in disease activity index (DAI) (bottom). **C)** Colon length, **D)** Spleen weight and **E)** Histology score on day 7. *= p < 0.05, **= p < 0.01, ***= p < 0.001.


A**B****50 mg/kg curcumin**

Supplementary Figure 2


A




B



C



D



E

